Retrotope Leadership

did postdoctoral research in the Department of Biochemistry, University of Oxford, UK, from 1995 to 2000, focusing on the overlap of bioorganic, combinatorial and surface chemistries. From 2000 to 2002 (San Diego, USA), and from 2002 to 2006 (UK) he worked in the biotech industry developing chemical tools for genomics and proteomics. At Retrotope, Dr. Shchepinov has focused on the use of stable isotopes as a fortification of essential nutrients to protect against diseases of aging and age-related oxidative stress. Dr. Shchepinov received his MS in chemistry and biotechnology from the Mendeleev Institute of Chemical Technology, Moscow, USSR, and a PhD in bioorganic chemistry from the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, in 1994.

Peter cofounded Optivia Biotechnology a leading transporter biology company. In 1997 Peter co-founded ARYx Therapeutics (NASDAQ:ARYX) where as CEO then as president from 2005 to 2010 he co-invented and developed 4 novel drugs. In 1990 he co-founded CV Therapeutics (NASDAQ:CVTX), where as a member of senior management from 1992-1996 he in-licensed and invented several successful pharmaceuticals.

Anil Kumar (born 1958) is an Indian-American former senior partner and director at management consulting firm McKinsey & Company, where he co-founded McKinsey's offices in Silicon Valley and India and created its Internet practice (representing a quarter of McKinsey's business at the time) among others. Kumar is additionally the co-founder of the Indian School of Business with Rajat Gupta and the creator of two different kinds of outsourcing. He graduated from IIT Bombay in India, Imperial College in the UK, and The Wharton School in the US.

I am a pharma executive with about 20 years of R&D and program management/leadership experience in the biotech/pharmaceutical industry. I have a proven record of delivering on development programs from early preclinical phase through Phase 3 and have led multiple cross functional teams, including product development and global clinical development teams.

My experience spans drug development in multiple therapeutic areas including Type II diabetes, anti-infective, osteoporosis, hormone replacement therapy, and central nervous system disorders such as fibromyalgia, Parkinson’s disease, and ALS, several drug delivery technologies (transdermal, pulmonary, parenteral, oral) and chemical entities.

My strengths include strategic and tactical problem solving skills as well as functional and operational leadership.

did postdoctoral research in the Department of Biochemistry, University of Oxford, UK, from 1995 to 2000, focusing on the overlap of bioorganic, combinatorial and surface chemistries. From 2000 to 2002 (San Diego, USA), and from 2002 to 2006 (UK) he worked in the biotech industry developing chemical tools for genomics and proteomics. At Retrotope, Dr. Shchepinov has focused on the use of stable isotopes as a fortification of essential nutrients to protect against diseases of aging and age-related oxidative stress. Dr. Shchepinov received his MS in chemistry and biotechnology from the Mendeleev Institute of Chemical Technology, Moscow, USSR, and a PhD in bioorganic chemistry from the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, in 1994.

Anil Kumar (born 1958) is an Indian-American former senior partner and director at management consulting firm McKinsey & Company, where he co-founded McKinsey's offices in Silicon Valley and India and created its Internet practice (representing a quarter of McKinsey's business at the time) among others. Kumar is additionally the co-founder of the Indian School of Business with Rajat Gupta and the creator of two different kinds of outsourcing. He graduated from IIT Bombay in India, Imperial College in the UK, and The Wharton School in the US.